Condition: Tuberculous Pericarditis · HIV Status · Sponsor: University of Cape Town
The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10). This Phase 2b randomized, placebo-controlled, double-blinded trial will evaluate the efficacy and safety of RIF 35mg/kg compared 10mg/kg, added to standard first-line ATT, for the treatment of PCTB.
This description comes directly from the study's public registry record.
Mpumi U Maxebengula, BCom · 0727633386 · mpumi.maxebengula@uct.ac.za
Kishal Maxebengula, Dr · +27732515380 · kishal.lukhna@uct.ac.za
Always discuss trial participation with your own doctor first.
| Nelson Mandela Academic Hospital | Mthatha, Eastern Cape, South Africa | Not Yet Recruiting |
| Groote Schuur Hospital | Cape Town, Western Cape, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04521803